Toffoli G - Search Results

1

Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity.

Fragoulakis V, Roncato R, Fratte CD, Ecca F, Bartsakoulia M, Innocenti F, Toffoli G, Cecchin E, Patrinos GP, Mitropoulou C. Fragoulakis V, et al. Among authors: toffoli g. Am J Hum Genet. 2019 Jun 6;104(6):1158-1168. doi: 10.1016/j.ajhg.2019.04.017. Epub 2019 May 30. Am J Hum Genet. 2019. PMID: 31155283 Free PMC article.

2

Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients.

Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F, Mini E, Boiocchi M. Toffoli G, et al. Int J Cancer. 2003 Jan 20;103(3):294-9. doi: 10.1002/ijc.10847. Int J Cancer. 2003. PMID: 12471611

3

Pharmacogenetics of irinotecan.

Toffoli G, Cecchin E, Corona G, Boiocchi M. Toffoli G, et al. Curr Med Chem Anticancer Agents. 2003 May;3(3):225-37. doi: 10.2174/1568011033482477. Curr Med Chem Anticancer Agents. 2003. PMID: 12769780 Review.

4

Pharmacogenetics of stomach cancer.

Toffoli G, Cecchin E. Toffoli G, et al. Suppl Tumori. 2003 Sep-Oct;2(5):S19-22. Suppl Tumori. 2003. PMID: 12914384 Review.

5

Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase.

Toffoli G, Rossi D, Gaidano G, Cecchin E, Boiocchi M, Carbone A. Toffoli G, et al. Int J Biol Markers. 2003 Jul-Sep;18(3):218-21. doi: 10.1177/172460080301800310. Int J Biol Markers. 2003. PMID: 14535593 Free article.

6

UGT1A1*28 polymorphism in ovarian cancer patients.

Cecchin E, Russo A, Corona G, Campagnutta E, Martella L, Boiocchi M, Toffoli G. Cecchin E, et al. Among authors: toffoli g. Oncol Rep. 2004 Aug;12(2):457-62. Oncol Rep. 2004. PMID: 15254716

7

Lack of association of CYP1 B1*3 polymorphism and ovarian cancer in a Caucasian population.

Cecchin E, Russo A, Campagnutta E, Martella L, Toffoli G. Cecchin E, et al. Among authors: toffoli g. Int J Biol Markers. 2004 Apr-Jun;19(2):160-3. doi: 10.1177/172460080401900212. Int J Biol Markers. 2004. PMID: 15255550 Free article.

8

Pharmacogenomics and stomach cancer.

Toffoli G, Cecchin E. Toffoli G, et al. Pharmacogenomics. 2004 Sep;5(6):627-41. doi: 10.1517/14622416.5.6.627. Pharmacogenomics. 2004. PMID: 15335285 Review.

9

Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.

Toffoli G, Cecchin E. Toffoli G, et al. J Chemother. 2004 Nov;16 Suppl 4:31-5. doi: 10.1179/joc.2004.16.Supplement-1.31. J Chemother. 2004. PMID: 15688606 Review.

10

Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.

Cecchin E, Corona G, Masier S, Biason P, Cattarossi G, Frustaci S, Buonadonna A, Colussi A, Toffoli G. Cecchin E, et al. Among authors: toffoli g. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6901-7. doi: 10.1158/1078-0432.CCR-05-0602. Clin Cancer Res. 2005. PMID: 16203781

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

352 results

Search Page

Filters